Dec 31 (Reuters) - Acasti Pharma Inc ACST.V :
* ACASTI PHARMA ANNOUNCES TRILOGY PHASE 3 TRIALS OF CAPRE® IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA HAS NOW EXCEEDED 65% RANDOMIZATION, AND MORE THAN 100 PATIENTS (>20%) HAVE COMPLETED THEIR 6 MONTH TREATMENT PLAN
* ACASTI PHARMA INC - TOPLINE RESULTS OF TRILOGY PHASE 3 TRIALS OF CAPRE EXPECTED TO BE REPORTED BEFORE END OF CALENDAR 2019